Catalyst Dossier · compiled by CeliA 🧫
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Biological Products, (No Diagnostic Substances) · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-31 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Creative Medical Technology Holdings (CELZ) is a micro-cap biotech with a $3M market cap, 4 employees, and two Phase 2 assets — CELZ-201 for Type 1 Diabetes and CELZ-201-DDT for Chronic Low-back Pain — with $5.7M cash providing roughly 13 months of runway. The company has generated no revenue across its recorded history and remains entirely dependent on external financing to advance its pipeline. The next meaningful readout is an estimated January 2027 Phase 2 data event for CELZ-201 in T1D, rated 7/10 importance.
The catalyst path
- 2027-01-31 (est.)Phase 2 · CELZ-201 Administrationimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CELZ-201 Administration | Phase 2 | Type 1 Diabetes |
| CELZ-201-DDT | Phase 2 | Chronic Low-back Pain |
Price & technical context
3-month
+6.2%
6-month
-56.9%
12-month
+13.8%
52-wk range
$1.78–$5.59
vs 50-day MA
+10.0%
vs 200-day MA
-15.5%
Realized vol
97.4%
Max drawdown
-72.4%
Daily closes through 2026-04-29. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELZ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.